Presenter's Information
Martin Bert Leon, MD
Country | USA |
Specialty | Interventional Cardiologist |
- An Introduction of APOLLO Trial
- Contemporary Trends in Aortic Stenosis Management - Legend's Perspective
- The UPSTREAM Management of Aortic Stenosis
- TAVR Long Journey: Chain of RCTs, Guideline Changes, and Future Directions
- TAVR Long-Term Durability: Is It Concerned for Late-Catch Up in PARTNER-3?
- The Future of TAVR: A Master's Perspectives
- Results and Update from the Vessix RE-INFORCE Program
- PARTNER-3 Low-risk TAVR
- Sapien 3 Clinical Update
- PARTNER 2A - TAVR in Intermediate Risk Patients
- Congratulatory Remark & Keynote Lecture: "Interventional Cardiology Transitions to Structural Heart Disease"
- Efficacy and Safety of TAVR 2016
- TAVR in Lower Risk
- TAVR Should Replace Surgery in (Almost) ALL Aortic Stenosis Patients
- The Odyssey of TAVR: From Concept to Clinical Reality
- New TAVR Systems and Accessory Devices
- Interventional Cardiovascular Medicine: Past, Now and Future Perspectives
- New TAVI Devices
- Dedicated Bifurcation Stents for True Coronary Bifurcation Lesions
- Results of Resolute Series of Studies
- Update of Dedicated Bifurcation Stent
- TAVR Update 2012: The Year in Review
- TAVI Update 2012: The Year in Review
- Complications After TAVR: Frequency and Clinical Importance
- Beyond DES: Peripheral Vascular Disease, TAVI and Hypertension
- Transcatheter Aortic-Valve Implantation for Aortic Stenosis in Patients Who Cannot Undergo Surgery
- PARTNER Percutaneous Transaortic Valve Implantation: What Have We Learned?
- Perspectives from PARTNER Trial
- Life after PARTNER (Inoperable and ¡°High Risk¡± Cohorts): Will TAVI Therapy Change Guidelines for AS Patients?
- DES of the Future: Design Goals and Challenges
- Predicting the Future for Transcatheter Valve Therapies: New Devices and Expanded Clinical Indications
- Status Update and Clinical Impact of Transcatheter Aortic Valve Implantation (TAVI)
- My Crystal Ball - New Drug Delivery Platforms and Bioabsorbable Stents will Dominate in the Next 5-10 Years!
- Therapy in Evolution: Percutaneous Aortic Valve Replacement
- Endeavor Program Overview
- Long-Term Clinical Outcome of Sirolimus-Eluting Stent over 6 Years
- Future Perspective of Bifurcation Stenting
- DES Should Be Favored
- The Changing Landscape of DES Use Patterns: Finally Stabilizing or Still in Transition?
- Is Transcatheter AVR the Standard of Care for High Risk AS Patients? Summary of Worldwide Experiences
- ENDEAVOR IV: 2-Year FU Comparing Zotarolimus- vs. Paclitaxel-Eluting Stents
- Addressing the Controversy of Late DES Thrombosis
- DES Safety Concerns: Impact on Clinical Practice
- The Changing Epidemiology of Valvular Heart Disease: Implications for Interventional Treatment Alternatives
- The Spectrum of Dedicated Stents for Bifurcation Lesions: Current Status and Future Projections
- Overview of Percutaneous Valve Therapy
- A Critical Appraisal of Percutaneous Aortic Valve Therapies: Device Concepts, Clinical Outcomes, and Future Projections
- New DES Drug Carrier Systems: Biostable, Bioabsorbable, and No Polymers, Elution Kinetics, and Beyond!
- THE GREAT DEBATE : All Patients Should Receive a Drug Eluting Stent - PRO